Introduction
Signaling pathways that mediate the proliferation and differentiation of hematopoietic cells include mitogen activated protein (MAP) kinase cascades. Of the three well-characterized MAP kinase pathways, extracellular signal-regulated (ERK) MAP kinase pathway is activated in response to various mitogenic signals such as growth factors and phorbol esters 1 whereas c-jun N-terminal kinase (JNK) and p38 MAP kinase pathways are activated by cellular stress signals such as heat shock, UV light and proinflammatory cytokines. 2 Activation of MAP kinase pathways results in phosphorylation and activation of transcription factors such as CREB, ATF-1, ATF-2, and c-jun. The CREB and ATF-1 transcription factors are phosphorylated and activated by ERK and p38 MAP kinase pathways. [3] [4] [5] Upon activation, they bind the c-AMP response elements (CRE) and activate transcription in response to a variety of extracellular signals. 4 Another member of the ATF/CREB family, ATF-2, is phosphorylated and activated by JNK and p38 MAP kinase pathways. 6, 7 In addition, activation of JNK leads to the phosphorylation and activation of the transcription factor, c-jun. 8 Upon activation, these transcription factors regulate expression of target genes that contribute to the biological response.
All three MAP kinase pathways are known to be activated by hematopoietic cytokines. [9] [10] [11] [12] [13] [14] [15] FL has been shown to activate ERK MAP kinases in a murine hematopoietic cell line, BaF3. This cell line stably expresses human Flt3 and the ERK MAP kinase activation is necessary for FL-induced cell proliferation. 16 G-CSF has been shown to activate all three MAP kinases in hematopoietic cell lines. 7, 15, 17 Furthermore, ERK and p38 MAP kinase pathways were shown to be necessary for G-CSF-induced hematopoietic cell proliferation. 17 However, it is likely that hematopoiesis in vivo is mediated by a complex interplay of signaling pathways activated by multiple cytokines. Administration of FL into mice stimulates the generation of many hematopoietic cell types including progenitor cells, lymphocytes and dendritic cells. 18 G-CSF plays a role in mobilization of CD34
+ progenitor cells and the generation of neutrophils. 19, 20 FL and G-CSF in combination exhibit a synergistic effect in mobilizing progenitor cells of multiple hematopoietic lineages. [21] [22] [23] [24] Progenipoietin (ProGP) is a family of chimeric proteins with both Flt3 and G-CSF receptor agonist activities and exhibits a synergistic effect in generation of CFU-GM in vitro and in mobilization of white blood cells in vivo in mice. 25 The regulation of MAP kinase pathways and gene expression in response to FL and G-CSF was examined in OCI-AML5, a human acute myeloid leukemic cell line that expresses Flt3 and G-CSF receptor (G-CSFR) and proliferates in response to FL and G-CSF. Effects of FL, G-CSF, FL+G-CSF and ProGP-1 on activation of MAP kinase pathways were investigated at the level of phosphorylation of ERK, JNK and p38 kinases and gene regulation. This report presents evidence that both FL and G-CSF stimulate the ERK pathway whereas G-CSF, but not FL, activates the p38 kinase pathway. The JNK pathway was not activated by either FL or G-CSF. Activities of ERK as well as p38 MAP kinase pathways are required for the optimal cell proliferation in response to either G-CSF or FL. G-CSF and FL induce expression of cell cycle genes that are known to be the targets of MAP kinase pathways. The data show a strong correlation between the level of activation of MAP kinase pathways, and the induction of genes involved in cell cycle and cell proliferation.
Materials and methods

Chemicals, cytokines, antibodies and kinase inhibitors
All reagents were obtained from Sigma (St Louis, MO, USA) unless noted otherwise. Recombinant hIL-3, hG-CSF, hFL, ProGP-1 and cytokine neutralizing antibodies were produced at Pharmacia Corporation (Searle, St Louis, MO, USA). 25 Protein G-plus agarose and protein-specific antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-specific antibodies were obtained from New England Biolabs (Beverly, MA, USA). Anti-phosphotyrosine antibody, 4G10 was purchased from Upstate Biotechnology (Waltham, MA, USA). MEK inhibitor PD 98059 and p38 kinase inhibitor 245 SB 203580 were purchased from Calbiochem (La Jolla, CA, USA).
Cell culture and proliferation assays
OCI-AML5 cells were purchased from the German Collection of Micro-organisms and Cell Cultures (DSM, Braunschweig, Germany). Cells were grown in ␣-MEM (GIBCO/BRL, Grand Island, NY, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS), 2 ng/ml each of hIL-3, hG-CSF and hFL. Cell proliferation assays were performed as described previously. 25 Briefly, OCI-AML5 cells were seeded at 2.5 × 10 4 cells/well in 96-well microtiter plates containing serial dilution of G-CSF, FL, ProGP-1 or FL+G-CSF in serum-free IMDM, human transferrin (100 g/ml), lipid substitute of 2.5 mg phosphatidyl choline/ml, bovine serum albumin (500 g/ml), and 2-mercaptoethanol (50 M). After 60 h, cells were pulsed with methyl-3 H-thymidine at 0.5 Ci per well for 6 h, harvested and incorporated radioactivity was measured by scintillation spectroscopy. To examine the effects of neutralizing antibodies on ProGP-1 activity, proliferation assay was performed as above, in the presence of 10 g/ml affinity purified antibodies raised against G-CSF and FL. No deleterious effects were observed when these antibodies were tested for toxicity to cells at high concentrations (unpublished observations). For studies with kinase inhibitors, cells were treated with inhibitors or DMSO (solvent control) at 37°C for 30 min before cytokine stimulation. The concentration of DMSO used as solvent control for inhibition studies was р0.1% at the highest concentration in the assay.
Cell stimulation and preparation of cell lysates
Cell lysates were prepared as described previously. 16 Briefly, OCI-AML5 cells were serum deprived for 16 h in ␣-MEM supplemented with 2% BSA. Cells were then stimulated with 10 nM G-CSF, FL, ProGP-1 or FL+G-CSF for 5, 10, 30 or 45 min at 37°C. After incubation with cytokines, cells were washed once with ice-cold PBS supplemented with protease and phosphatase inhibitors and lysed in ice-cold RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyfluoride, 1 mg/ml each of aprotinin, leupeptin and pepstatin, 1 mM sodium orthovanadate and 1 mM NaF). Cell lysates were centrifuged at 14 000 g for 15 min and the supernatant aliquoted and stored at −80°C until ready to use. The protein concentration in the supernatant was determined using a BioRad (Hercules, CA, USA) protein assay kit. For studies involving kinase inhibitors, cells were treated with inhibitors at 37°C for 30 min before cytokine stimulation and the cell lysates were prepared as described above.
Immunoprecipitation, SDS-PAGE and immunoblotting
Immunoprecipitation was carried out according to previously described methods. 16 Briefly, cell lysates (0.5-1 mg) were incubated with 5 g of anti-phosphotyrosine antibody 4G10 and protein G-plus agarose for 2 h at 4°C. Immune complexes were washed three times with lysis buffer and heated in SDS/DTT containing loading buffer. Immunoprecipitates or whole cell lysates were separated by SDS-PAGE on 4-12% pre-cast Nupage gels (Invitrogen, Carlsbad, CA, USA). Gels Leukemia were transferred on to nitrocellulose membranes (Sigma), probed with the indicated primary antibody and appropriate horseradish peroxidase-conjugated secondary antibody and detected by enhanced chemiluminescence (Pierce, Rockford, IL, USA). For quantification of band intensity, the western blots were scanned using a densitometer (Molecular Dynamics, Palo Alto, CA, USA).
TaqMan real time quantitative RT-PCR analysis
OCI-AML5 cells were starved for 16 h in ␣-MEM supplemented with 2% FBS. Cells were stimulated with 10 nM cytokines for 1, 2, 4, 8 and 20 h. Total RNA was extracted from untreated and treated cells using RNAqueous-Midi kit (Ambion, Austin, TX, USA) and treated with DNAse I for removal of residual DNA. 'TaqMan Human Cell Growth and Regulation Card' containing TaqMan primers and probes in quadruplicates for 24 cell growth and regulation-related genes was obtained from Applied Biosystems (Foster City, CA, USA). Each well also contained TaqMan primers and probes for 18S rRNA for normalization. 250 ng of total RNA from each sample was converted to first-strand cDNA using TaqMan Reverse Transcription reagents (Applied Biosystems) and added to a TaqMan card according to the manufacturer's instructions. Real time quantitative RT-PCR assays were run on ABI PRISM 7700 and analyzed using the Sequence Detection System software according to the manufacturer's instructions (Applied Biosystems).
Results
FL and G-CSF stimulate proliferation of OCI-AML5 cells
OCI-AML5 is a cytokine-dependent human acute myeloid leukemia cell line that proliferates in response to FL and G-CSF 26, 27 and therefore provides a convenient experimental system to study intracellular signaling events induced by FL and G-CSF. The effect of FL or G-CSF was compared to the co-addition of individual cytokines (FL+G-CSF) or a chimeric molecule, ProGP-1. ProGP-1 was designed to exploit the synergistic effect of FL and G-CSF combination in a single molecular entity. 25 ProGP-1 binds both Flt3 and G-CSFR with high affinity (K d of 39 ± 6 and 0.62 ± 0.24 nM, respectively) and induces the proliferation of FL and G-CSF-responsive cell lines. 25 First, the response of OCI-AML5 cells to FL and G-CSF was examined in a 3 H-thymidine incorporation assay. OCI-AML5 cells proliferated in response to G-CSF, FL, FL+G-CSF and ProGP-1 in a dose-dependent manner ( Figure 1a ). G-CSF was a potent stimulator of proliferation with an EC 50 of 6.2 ± 0.8 pM {means of four replicate experiments ± s.e.m.}. FL was a weaker stimulator of proliferation with an EC 50 of 164 ± 13 pM and much lower maximal response. The potency of G-CSF, ProGP-1 (EC 50 = 7.5 ± 3.5 pM) and FL+G-CSF (EC 50 = 8.9 ± 3.7 pM) were equivalent as reflected in their comparable EC 50 values. A small but consistent increase in the maximum proliferation induced by ProGP-1 and FL+G-CSF compared to G-CSF alone was observed.
To demonstrate the relative contribution of Flt3 and G-CSFR agonist activities of ProGP-1, cell proliferation assays in the presence of neutralizing antibodies to G-CSF and FL were performed. Individually, G-CSF and FL antibodies at a concentration of 10 g/ml exhibited Ͼ95% inhibition of proliferation induced by 10 nM G-CSF and FL, respectively, suggesting that these antibodies indeed neutralized the activity G-CSF and FL (data not shown). As shown in Figure 1b , neutralizing antibodies to G-CSF and FL significantly attenuated the ProGP-1 response when added individually and completely abolished the response when added together. Anti-G-CSF antibody had a greater effect on inhibition of proliferation than anti-FL antibody suggesting a greater contribution of G-CSF towards total proliferative activity of ProGP-1 in OCI-AML5 cells. Antibody inhibition of FL+G-CSF response was similar to that of ProGP-1 (data not shown). These data suggest that both G-CSF and Flt3 receptor agonist activities contribute to the activity of ProGP-1.
FL and G-CSF stimulate tyrosine phosphorylation of Flt3 and G-CSFR, respectively
G-CSFR belongs to the non-tyrosine-kinase receptor family whereas Flt3 is a member of the class III receptor tyrosine kinases. Both the Flt3 and G-CSF receptors undergo tyrosine phosphorylation upon binding to their respective ligands. 16, 28 To examine the phosphorylation events induced by FL, G-CSF, ProGP and FL+G-CSF, immunoprecipitation with antiphosphotyrosine antibody and immunoblotting with anti-G-CSFR and anti-Flt3 antibodies were performed on lysates prepared from OCI-AML5 cells stimulated with G-CSF, FL, FL+G-CSF and ProGP-1. A rapid tyrosine phosphorylation of G-CSFR in response to G-CSF and of Flt3 in response to FL was observed ( Figure 2 ). In the time-course study of phosphorylation shown in Figure 2 , the peak of phosphorylation for both receptors was observed at 5 min and started to decline thereafter. FL+G-CSF and ProGP-1 induced phosphorylation of both G-CSFR and Flt3, and the kinetics and magnitude of phosphorylation of each receptor was similar to that induced by G-CSF and FL alone. 
Activation of MAP kinases by FL and G-CSF
In order to investigate intracellular signaling pathways that are activated by G-CSF and FL, activation of ERK, JNK and p38 MAP kinases was examined. Each MAP kinase is maximally activated by an upstream dual specificity kinase that phosphorylates a Thr and a Tyr residue in the kinase domain. Since there is a tight correlation between the phosphorylation of these Thr and Tyr residues and the activation of the kinases, dual phosphorylation was used as an indirect measure of acti-247 vation of these MAP kinases. Antibodies that detect MAP kinases only when dually phosphorylated at the activating Thr and Tyr residues were used to measure the relative levels of phosphorylation of individual MAP kinases.
Anti-phospho-p44/42 MAP kinase (Thr202/Tyr204) antibody which detects ERK1 and ERK2 (ERK1/2) only when dually phosphorylated at Thr202 and Tyr204 was used to investigate the phosphorylation of ERK1/2 upon stimulation of OCI-AML5 cells with various cytokines. Treatment of OCI-AML5 cells with G-CSF and FL either alone or in combination resulted in a rapid and transient phosphorylation of ERK1/2. The peak of ERK1/2 phosphorylation was observed at 5 min and started to decline thereafter (Figure 3a) . G-CSF, ProGP-1 and FL+G-CSF induced a similar magnitude of ERK1/2 phosphorylation. The magnitude of FL-induced phosphorylation was substantial, although not as great as stimulation with any of the other factors.
Anti-phospho-p38 MAP kinase (Thr180/Tyr182) antibody that detects p38 MAP kinase only when activated by dual phosphorylation at Thr180 and Tyr182 was utilized to examine the activation of p38 MAP kinase in response to cytokines. G-CSF stimulation of OCI-AML5 cells resulted in increased phosphorylation of p38 MAP kinase (Figure 3b ). In contrast to the kinetics of ERK1/2 phosphorylation, the p38 MAP kinase phosphorylation was gradual and the phosphorylated form reached a peak at 30 min and declined thereafter. There was no induction of phosphorylation of p38 kinase above the basal Leukemia level in FL-treated cells. Densitometric scanning revealed that the apparent slight increase in the phosphorylation of p38 kinase induced by FL at 45 min is not significant. There was no significant difference in the kinetics or the magnitude of phosphorylation of p38 kinase induced by G-CSF, G-CSF+FL and ProGP-1 treatments.
Phosphorylation of JNK1 and JNK2 in response to G-CSF and FL was investigated using an anti-phospho-JNK (Thr183/Tyr185) antibody. There was no detectable induction of phosphorylation of JNK1 in response to G-CSF and FL above the basal level (Figure 3 ) whereas JNK2 phosphorylation was not detected at all. Taken together, these results suggest that G-CSF activates both ERK and p38 MAP kinases whereas FL activates only ERK1/2 in OCI-AML5 cells. There was no evidence for either qualitative or quantitative differences between G-CSF, FL+G-CSF and ProGP-1 treatments in the activation of MAP kinases. There was no evidence of induction of phosphorylation of the transcription factor c-jun, (Figure 4c ) further confirming the lack of activation of JNK kinase in response to any of the cytokines tested. Taken together, these data demonstrate that ERK and p38 MAP kinase pathways are activated by G-CSF while FL activates mainly the ERK pathway.
Activation of ERK and p38 MAP kinase-regulated transcription factors by FL and G-CSF
Activation of ERK and p38 MAP kinase pathways is required for cytokine-stimulated proliferation of OCI-AML5 cells
In order to assess the roles of ERK and p38 MAP kinase pathways in cytokine-induced proliferation of OCI-AML5 cells, effects of specific inhibitors of ERK and p38 MAP kinase pathways on cell proliferation were investigated. PD 98059 is a flavone compound that selectively inhibits activation of MEK1 and MEK2 and therefore blocks ERK activation 29 whereas SB 203580 is a pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. 30 As shown in Figure 5 , treatment with PD 98059 resulted in inhibition of G-CSF, FL, ProGP-1 and the FL+G-CSF-induced proliferation in a dose-dependent manner. At 50 M, PD 98059 inhibited nearly 90% of proliferation induced by any of the cytokine treatments. Similarly, treatment with SB 203580 diminished proliferation of cells in response to G-CSF, FL, ProGP-1 and FL+G-CSF in a dose-dependent manner. There was a near complete inhibition of proliferation in the presence of 50 M SB 203580. At 50 and 10 M, inhibition of proliferation by PD 98059 and SB 203580 were statistically significant (P Ͻ 0.05). Simultaneous treatment of cells with both inhibitors showed an additive effect on inhibition of proliferation. At all concentrations tested, inhibition of proliferation by PD 98059 and SB 203580 combined was higher than that with either inhibitor alone. In contrast to individual inhibitor treatments, there was a statistically significant (P Ͻ 0.05) inhibition of proliferation by 5 and 1 M of the two inhibitors combined. These data suggest that activities of both ERK and p38 MAP kinase pathways are required for optimal cell proliferation in response to G-CSF and FL.
Regulation of gene transcription by FL and G-CSF
To further extend the studies on activation of ERK and p38 MAP kinase pathways, regulation of transcription of some of Inhibition of cytokine-induced proliferation of OCI-AML5 cells by PD 98059, a MEK inhibitor and SB 203580, a p38 kinase inhibitor. Cells were pretreated with the indicated concentrations of PD 98059, SB 203580 or both for 30 min and proliferation response to 10 nM of the indicated cytokine was measured by 3 Hthymidine incorporation. Proliferation is expressed as % of control (containing 10 nM cytokine plus 0.1% DMSO). The values for control proliferation were 11 077 ± 1547 (G-CSF), 5420 ± 105 (FL), 14 653 ± 479 (ProGP) and 12 777 ± 965 (G-CSF+FL). The inhibition of proliferation by MEK and p38 kinase inhibitors is expressed as mean of triplicate experiments ± s.e.m. Statistical analysis was performed using one-sided t-test with Satterthwaites adjustment for unequal variance. *Treatments statistically different from the control, (P Ͻ 0.05).
the putative target genes was investigated. The genes listed in Table 1 were selected by Applied Biosystems in an effort to design a diagnostic tool (TaqMan human cell growth and regulation card) for studying cell growth and regulation. All of these genes are known to be transcriptionally regulated by one or more signals critical for cell proliferation, differentiation or apoptosis. TaqMan cell growth and regulation cards Leukemia Table 1 Genes present in the TaqMan human cell growth and regulation card Gene Regulation
No significant regulation (Ͻthree-fold change) by any of the cytokines; +, significant regulation (Ͼthree-fold change) by at least one of the cytokines; ND, the message is not detected under the experimental conditions.
were used to investigate the regulation of these genes in response to G-CSF, FL, FL+G-CSF and ProGP-1. Transcript levels for the 24 genes listed in Table 1 were measured in cells stimulated with G-CSF, FL, ProGP-1 and FL+G-CSF for 1, 2, 4, 8 and 20 h. Expression levels of the genes were normalized to the levels of 18S rRNA included as a control in the TaqMan card. As indicated in Table 1 , of 24 genes, transcripts for 12 genes were not significantly regulated and transcripts for four genes were not detected by any of the cytokine treatments. Eight genes that were significantly regulated (a differential expression of three-fold or more) by one or more cytokine treatments are discussed below.
MKP1 is a dual-specific phosphatase that can dephosphorylate phosphotyrosine and phosphothreonine containing proteins and is known to inactivate ERKs, JNKs and p38 MAP kinases. 31 As shown in Figure 6 , a dramatic up-regulation of MKP1 mRNA was observed after 1 h of treatment of OCI-AML5 cells with G-CSF (20-fold), FL (12-fold), ProGP-1 (ninefold) and FL+G-CSF (nine-fold). The up-regulation of MKP1 was transient since the message levels for MKP1 returned to basal levels after 2 h of treatment.
The expression of c-fos, an immediate-early gene encoding a transcription factor was induced five-to seven-fold after 1 h of treatment of cells with G-CSF, FL, ProGP-1 and FL+G-CSF and returned to basal level thereafter ( Figure 6 ). In contrast, c-myc was gradually up-regulated over time by the cytokine treatments ( Figure 6 ). The increase in c-myc transcript level was between seven-and 17-fold in G-CSF, FL, ProGP-1 and FL+G-CSF-treated cells at 20 h. Up-regulation of c-myc transcript level was much lower in FL-treated cells at earlier timepoints (4 and 8 h) although by 20 h, FL-induced c-myc expression was comparable to that of other treatments. As shown in Figure 6 , E2F1 mRNA level increased above basal The time-course of induction of cyclins, cyclin D1 and cyclin E1 approximately followed that of c-myc in response to cytokine treatments (Figure 7) . Increases in transcript levels were observed after 4 h of cytokine treatment and continued until 20 h. Interestingly, cyclin D1 levels were not significantly affected in FL-treated cells. However, all four cytokine treatments resulted in up-regulation of cyclin E1 mRNA level after 8 h of treatment. The lack of significant increase in cyclin D1 level and a lower level of increase in cyclin E1 by FL compared to other cytokine treatments correlated well with the slower and weaker c-myc induction in FL-treated cells. There was an increase in the level of TERT mRNA at 8 h that was
Figure 7
Transcriptional regulation of cyclin D1, cyclin E1, PCNA and TERT by G-CSF and FL. OCI-AML5 cells were stimulated with 10 nM of the indicated cytokines for 1, 2, 4, 8 and 20 h, total RNA was extracted and the level of transcripts for the indicated gene was measured by TaqMan real time RT-PCR. mRNA levels for each gene were normalized to the level of 18S rRNA. Expression of each gene is represented as ratio of mRNA level in treated samples vs 0 h control. Greater than three-fold change in relative expression (indicated by dotted lines) was considered as significant. further elevated at 20 h after cytokine treatments (Figure 7) . PCNA mRNA was also up-regulated after 20 h of treatment ( Figure 7) . Again, FL treatment resulted in a slower and weaker induction of PCNA and TERT transcripts. However, there was no significant difference between G-CSF, FL+G-CSF and ProGP-1 treatments in induction of any of the genes studied.
The results from the gene regulation studies provide evidence that G-CSF, FL and ProGP-1 and FL+G-CSF induce transcription of several genes whose products are involved in signaling (MKP1), transcription (c-myc, c-fos and E2F1), DNA replication and repair (PCNA and TERT) and cell cycle regulation (cyclin D1 and cyclin E1). These findings combined with the results from studies on MAP kinase activation strongly suggest that G-CSF, FL, FL+G-CSF and ProGP-1 cause proliferation of hematopoietic cells, at least in part, via ERK and p38 MAP kinase pathways leading to the up-regulation of several transcription factors, which in turn induce transcription of genes involved in DNA replication and cell cycle.
Discussion
Based on the synergy between FL and G-CSF in the mobilization of hematopoietic progenitor cells, [32] [33] [34] activation of intracellular signaling pathways and regulation of gene transcription by G-CSF and FL alone and in combination were examined in a hematopoietic cell line. G-CSF and FL both stimulate proliferation of OCI-AML5 cells, however, G-CSF was more potent than FL. For OCI-AML5 cells, an additive effect between G-CSF and FL on cell proliferation was observed both in the context of co-addition of the G-CSF and FL or a chimeric molecule, ProGP-1.
G-CSF and FL stimulate activation of ERK MAP kinase pathway as shown by the stimulation of phosphorylation of ERK1 and ERK2 MAP kinases and CREB and ATF-1 transcription factors. Upon activation, ERK pathway is known to induce phosphorylation of CREB at Ser133 4 and ATF-1 at Ser63 and activate their transcriptional activity.
5 G-CSF and FL rapidly induce dual phosphorylation of ERK1/2 ( Figure 3a ) and phosphorylation of CREB and ATF-1 (Figure 4a ). FL is a weaker stimulator of ERK1/2 and CREB/ATF-1 phosphorylation than G-CSF, which correlates well with its reduced capacity to stimulate proliferation of these cells. FL+G-CSF or ProGP-1 did not exhibit an additive effect over G-CSF or FL alone in inducing phosphorylation of ERK1/2 and CREB/ATF-1. One possible explanation is that phosphorylation of ERK1/2 and CREB/ATF-1 has reached a maximum in response to G-CSF and could not be further enhanced.
Stimulation of OCI-AML5 cells with G-CSF, FL+G-CSF and ProGP1 resulted in phosphorylation of p38 kinase with similar kinetics while FL did not induce phosphorylation of p38 kinase above the basal level (Figure 3b ). This could be a possible reason for the lower level of OCI-AML5 cell proliferation induced by FL since both ERK and p38 MAP kinase pathways appear to be required for proliferation of these cells. In contrast to the kinetics of ERK1/2 phosphorylation, induction of p38 kinase phosphorylation was gradual and was sustained for a longer period of time. This result is quite distinct from the peak phosphorylation of p38 kinase that was observed at 5 min after G-CSF stimulation in murine pre-B precursor cell line BaF3 17 as well as a complete lack of phosphorylation of p38 kinase in response to G-CSF in human neutrophils.
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These differences may be due to the inherent differences between the different cell types used in these studies. The transcription factor ATF-2 is phosphorylated and activated mainly by p38 kinase and JNK. 6, 7 The lack of correlation between the activation of p38 kinase by G-CSF, ProGP1 and FL+G-CSF and the phosphorylation of ATF-2 was surprising. It is possible that in OCI-AML5 cells, p38 kinase is not a major regulator of ATF-2 activity. In fact, it was recently reported that JNK pathway is a much more potent activator of ATF-2 than p38 kinase pathway in human neuroblastoma cells. 35 It is well established that the activity of the ERK pathway is essential for the mitogenic response of various cell types to growth factors. 1, 13, 36 Several reports published recently have shown that the p38 kinase pathway is required for the proliferation of several mouse and human cell lines of hematopoietic origin. 17, [36] [37] [38] Using specific chemical inhibitors, we show here that both ERK and p38 MAP kinase pathways are required for optimal proliferation of OCI-AML5 cells in response to both G-CSF and FL ( Figure 5 ). Either inhibitor Leukemia alone partially attenuated cell proliferation whereas the combination of the two inhibitors showed an additive effect on the inhibition of proliferation. It is interesting to note that a specific p38 kinase inhibitor, SB 203580, inhibits FL-stimulated proliferation although FL does not activate p38 kinase above the basal level. This suggests that the basal activity of p38 kinase present in OCI-AML5 cells appears to be necessary for FL-stimulated cell proliferation.
A hallmark of the activation of signaling pathways is the regulation of transcription of genes that contribute to the biological response to a given signal. MKP1, a dual specificity phosphatase is believed to be important for desensitization of MAP kinase pathways after the initial activation and for the maintenance of homeostasis. MKP1 is transcriptionally induced upon activation of ERK, p38 and JNK activation. 31 G-CSF and FL induce transcription of MKP1 with peak induction at 1 h after cytokine treatment ( Figure 6 ). It is possible that MKP1 plays a role in desensitization of ERK and p38 MAP kinases in these cells by turning on a 'negative feedback' loop to shut down further signaling.
Transcription factors that link activation of MAP kinases to regulation of transcription are themselves targets for transcriptional regulation. Transcription factors c-fos and c-myc are known to be transcriptionally regulated by the ERK pathway 39, 40 and are believed to be key regulators of cell proliferation. 41, 42 c-fos was up-regulated in an hour after treatment of OCI-AML5 cells with G-CSF and FL. c-myc was induced at 1 h after treatment with cytokines and was maintained up to 20 h ( Figure 6 ). Another transcription factor, E2F1, is up-regulated by mitogenic signals (at least partially through c-myc) and is thought to play a critical role in the induction of S phase of the cell cycle. 43 E2F1 mRNA was up-regulated 13-fold and five-fold in response to G-CSF and FL, respectively ( Figure 6 ). The time-course of induction of E2F1 follows that of c-myc consistent with a role for c-myc in E2F1 induction. FL was a slower and weaker inducer of c-myc and E2F1 levels compared to G-CSF which correlates well with the lower level of activation of ERK pathway by FL. c-myc is thought to play a role in transcriptional control of cyclins (D and E) and TERT among others, 44 whereas E2F1 induces transcription of cyclins (A and E) and PCNA. 43 We observed an up-regulation in the levels of cyclin D1 and PCNA in response to G-CSF and cyclin E1 and TERT in response to both G-CSF and FL (Figure 7) . The lower level of induction of these target genes by FL compared to G-CSF is consistent with the lower level of induction of c-myc and E2F1 by FL. Taken together, increases in PCNA, cyclin D1 and cyclin E1 levels suggest that OCI-AML5 cells are transitioning from G1 to S phase of the cell cycle around 20 h after stimulation with G-CSF and FL. Consistent with its lesser ability to stimulate ERK activation and/or inability to activate p38 kinase, FL causes a slower and weaker induction of expression of c-myc, E2F1, cyclin D1, cyclin E1 and PCNA compared to G-CSF. This may possibly lead to a slower kinetics of cell cycle progression and thus lower magnitude of proliferation in FL-treated OCI-AML5 cells.
FL and G-CSF exhibit a potent synergistic effect in the proliferation of hematopoeitic progenitor cells ex vivo and expansion and mobilization of stem cells in vivo. However, we have been unable to detect any synergistic effect between G-CSF and FL in cell proliferation, MAP kinase activation or gene induction in OCI-AML5 cells. One of the reasons could be that this synergy depends on the interaction among different cell types found in the heterogeneous mixture of hematopoietic stem cells or the complexity of an in vivo cellular environment. Perhaps, physiologically relevant bone marrow stem cells may provide a more useful experimental system to address the issue of synergy. However, activation of phosphorylation events in CD34 + stem cells is beyond the scope of this study. This is the first study to report FL-regulated expression of genes involved in cell cycle progression and how this relates to cell proliferation. The difference in the level of activation of the ERK pathway by FL compared to G-CSF remains to be addressed. One possible reason may be that Flt3 is expressed at a lower level than G-CSFR on the surface of OCI-AML5. In fact, OCI-AML5 cells express a four-to five-fold lower number of Flt3 than G-CSFR as determined by radioligand binding assay (unpublished observations). One way to address this question would be to ectopically express equivalent levels of G-CSFR and Flt3 and investigate the activation of the ERK pathway. It is also possible that inherently, G-CSF is more efficient in activating the ERK pathway than FL. This may be related to the fact that G-CSF is a strong proliferative factor whereas FL is predominantly a survival factor and acts in synergy with other cytokines to induce proliferation of hematopoietic progenitor cells 45, 46 as well as myeloid leukemic cells. 47, 48 These are some of the issues to be addressed in the future that will add to our understanding of Flt3-mediated signaling events.
In conclusion, proliferation of OCI-AML5 cells in response to G-CSF and FL is, at least in part, due to the activation of ERK and p38 MAP kinase pathways and the induction of expression of genes involved in cell cycle progression.
